Demonstrates cardioprotective benefits of combining a PPAR-γ agonist with melatonin in diabetes, highlighting the therapeutic potential of dual-action treatment.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ahire et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: